$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000115903622000014 Filed on February 22, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$102.0M	$115.8M	$443.3M
YoY Change	-16.19%	77.34%	65.67%
Cost Of Revenue	$21.59M	$18.59M	$81.41M
YoY Change	-17.92%	233.85%	87.73%
Gross Profit	$80.42M	$97.24M	$361.9M
YoY Change	1200.6%	2694.28%	61.4%
Gross Profit Margin	78.84%	83.95%	81.64%
Selling, General & Admin	$13.77M	$13.17M	$50.32M
YoY Change	32.44%	12.54%	10.03%
% of Gross Profit	17.13%	13.54%	13.91%
Research & Development	$10.11M	$8.486M	$35.67M
YoY Change	36.59%	9.54%	4.19%
% of Gross Profit	12.57%	8.73%	9.86%
Depreciation & Amortization	$773.0K	$700.0K	$3.000M
YoY Change	-3.38%	-12.5%	-9.09%
% of Gross Profit	0.96%	0.72%	0.83%
Operating Expenses	$23.88M	$21.66M	$86.00M
YoY Change	-45.82%	-13.44%	7.53%
Operating Profit	$56.53M	$75.59M	$275.9M
YoY Change	-249.18%	87.56%	91.26%
Interest Expense	-$1.724M	$1.754M	$7.526M
YoY Change	-60.82%	-64.85%	-63.07%
% of Operating Profit	-3.05%	2.32%	2.73%
Other Income/Expense, Net		$274.0K	$1.102M
YoY Change		-71.49%	-79.69%
Pretax Income	$54.81M	$74.11M	$248.5M
YoY Change	-25.12%	104.32%	92.2%
Income Tax	-$11.96M	$154.2M	-$154.2M
% Of Pretax Income	-21.82%	208.08%	-62.04%
Net Earnings	$66.77M	$216.6M	$402.7M
YoY Change	-8.74%	498.19%	211.97%
Net Earnings / Revenue	65.46%	186.99%	90.84%
Basic Earnings Per Share		$1.53	$2.86
Diluted Earnings Per Share	$462.9K	$1.48	$2.74
COMMON SHARES
Basic Shares Outstanding	140.8M shares	142.0M shares	140.6M shares
Diluted Shares Outstanding		146.7M shares	146.8M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$740.9M	$815.9M	$740.9M
YoY Change	101.33%	135.33%	101.34%
Cash & Equivalents	$118.7M	$491.7M	$118.7M
Short-Term Investments	$622.2M	$324.2M	$622.2M
Other Short-Term Assets	$40.48M	$33.30M	$40.48M
YoY Change	43.05%	4.39%	43.05%
Inventory	$53.91M	$55.98M	$53.91M
Prepaid Expenses	$47.99M	$43.32M
Receivables	$90.98M	$112.1M	$90.98M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$926.3M	$1.017B	$926.3M
YoY Change	66.97%	103.91%	66.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.791M	$7.163M	$8.794M
YoY Change	-6.88%	-30.13%	-17.04%
Goodwill	$0.00
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$169.3M	$158.5M	$169.3M
YoY Change	1059.92%	963.98%	1059.92%
Total Long-Term Assets	$178.1M	$168.1M	$178.1M
YoY Change	608.04%	568.9%	609.73%
TOTAL ASSETS
Total Short-Term Assets	$926.3M	$1.017B	$926.3M
Total Long-Term Assets	$178.1M	$168.1M	$178.1M
Total Assets	$1.104B	$1.185B	$1.104B
YoY Change	90.44%	126.21%	90.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.541M	$3.322M	$1.541M
YoY Change	-20.07%	667.21%	-18.89%
Accrued Expenses	$24.44M	$18.34M	$24.44M
YoY Change	19.32%	-28.92%	19.22%
Deferred Revenue	$1.746M
YoY Change	0.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$89.42M	$89.25M	$89.42M
YoY Change	-77.49%		-77.49%
Total Short-Term Liabilities	$117.1M	$113.2M	$117.1M
YoY Change	-72.2%	319.46%	-72.2%
LONG-TERM LIABILITIES
Long-Term Debt	$787.3M	$786.5M	$787.3M
YoY Change		99.81%
Other Long-Term Liabilities	$544.0K	$1.609M	$3.074M
YoY Change	-84.3%	-57.58%	-59.01%
Total Long-Term Liabilities	$787.8M	$1.609M	$790.3M
YoY Change	22629.34%	-57.58%	10437.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$117.1M	$113.2M	$117.1M
Total Long-Term Liabilities	$787.8M	$1.609M	$790.3M
Total Liabilities	$904.9M	$114.8M	$907.5M
YoY Change	113.0%	272.98%	111.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.91M	-$125.7M
YoY Change	-87.59%	-77.06%
Common Stock	$256.5M	$407.4M
YoY Change	-59.0%	-36.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$197.0M	$281.7M	$197.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.104B	$1.185B	$1.104B
YoY Change	90.44%	126.21%	90.45%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	$66.77M	$216.6M	$402.7M
YoY Change	-8.74%	498.19%	211.97%
Depreciation, Depletion And Amortization	$773.0K	$700.0K	$3.000M
YoY Change	-3.38%	-12.5%	-9.09%
Cash From Operating Activities	$82.52M	$121.7M	$299.4M
YoY Change	61.8%	1895.72%	439.98%
INVESTING ACTIVITIES
Capital Expenditures	-$158.0K	-$496.0K	$1.457M
YoY Change	-90.71%	148.0%	-41.81%
Acquisitions			$0.00
YoY Change
Other Investing Activities	-$299.3M	-$16.46M	-$404.8M
YoY Change	-597.19%	-44.96%	-600.41%
Cash From Investing Activities	-$299.5M	-$16.95M	-$406.3M
YoY Change	-611.91%	-43.67%	-618.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$150.0M		$350.1M
YoY Change			133.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-156.0M	-60.07M	$77.87M
YoY Change	469.38%	36.83%	-173.26%
NET CHANGE
Cash From Operating Activities	82.52M	121.7M	$299.4M
Cash From Investing Activities	-299.5M	-16.95M	-$406.3M
Cash From Financing Activities	-156.0M	-60.07M	$77.87M
Net Change In Cash	-373.0M	44.72M	-$28.98M
YoY Change	-554.28%	-165.86%	-205.3%
FREE CASH FLOW
Cash From Operating Activities	$82.52M	$121.7M	$299.4M
Capital Expenditures	-$158.0K	-$496.0K	$1.457M
Free Cash Flow	$82.67M	$122.2M	$298.0M
YoY Change	56.88%	1840.24%	462.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.halozyme.com/20211231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.halozyme.com/20211231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2019Q4	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P3Y
CY2021Q4	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P3Y
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-32335
CY2021	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS, INC.
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.21
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0488686
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	11388 Sorrento Valley Road
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Local Phone Number LocalPhoneNumber	794-8889
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2021	dei	Trading Symbol TradingSymbol	HALO
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	5600000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	137703510	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118719000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147703000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	622203000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	220310000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	90975000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	97730000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	53908000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	60747000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40482000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28274000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4965374	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	20.76
CY2021Q4	us-gaap	Assets Current AssetsCurrent	926287000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	554764000	USD
CY2021Q4	halo	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8794000	USD
CY2020Q4	halo	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10593000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	13414000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	14067000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	155434000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2021Q4	us-gaap	Assets Assets	1104429000	USD
CY2020Q4	us-gaap	Assets Assets	579924000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1541000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1928000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24441000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20483000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1746000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1746000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	89419000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	397228000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	117147000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	421385000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2530000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4026000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	787255000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	544000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3466000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	137498000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	137498000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135030000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135030000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	138000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	135000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	256347000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	625483000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-620000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58912000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-474593000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	196953000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	151047000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1104429000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	579924000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	443310000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20820000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17204000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34776000	USD
CY2021	halo	Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price Percent Of Share Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePricePercentOfSharePrice	1
CY2021	halo	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Initial Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingInitialContractualTerm	P10Y
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	267594000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	195992000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	81413000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	43367000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	45546000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35672000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34236000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	140804000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	50323000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45736000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	77252000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	167408000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	123339000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	263602000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	275902000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	144255000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-67610000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1102000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5425000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6986000	USD
CY2021	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	20960000	USD
CY2020	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2019	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2021	us-gaap	Interest Expense InterestExpense	7526000	USD
CY2020	us-gaap	Interest Expense InterestExpense	20378000	USD
CY2019	us-gaap	Interest Expense InterestExpense	11627000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	248518000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	129302000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-72251000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-154192000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	217000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	402710000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	129085000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-72240000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.86
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.74
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	140646000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	136206000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144329000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	146796000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141463000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144329000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	402710000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	20.74
CY2020	us-gaap	Net Income Loss NetIncomeLoss	129085000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-72240000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-683000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-164000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	508000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-15000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	32000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-9000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	26000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-22000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	402068000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	128867000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71723000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	402710000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	129085000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-72240000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	20820000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	17204000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	34776000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2997000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3284000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4068000	USD
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3642000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	14136000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2484000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2257000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-839000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2469000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	772000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1431000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.46
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4632000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1496000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4119000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3996000	USD
CY2021	halo	Deferred Rent Payments DeferredRentPayments	751000	USD
CY2020	halo	Deferred Rent Payments DeferredRentPayments	1033000	USD
CY2019	halo	Deferred Rent Payments DeferredRentPayments	459000	USD
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2020	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	577000	USD
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1127000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-401000	USD
CY2021	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	20960000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M21D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	101800000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3207090	shares
CY2020	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2019	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	155434000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-3000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-13000	USD
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-7000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6755000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38288000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29437000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7371000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	31388000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6734000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	11555000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2518000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19006000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1167000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-41208000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4638000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	299440000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	55454000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-85423000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	652515000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	226185000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	389759000	USD
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	247683000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	305967000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	388250000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1457000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2504000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4040000	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1076000	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-406289000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	78354000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5549000	USD
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	784875000	USD
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
CY2019	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	447350000	USD
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	369064000	USD
CY2020	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	19560000	USD
CY2019	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	108082000	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	424000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	279000	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	350058000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5633622	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.83
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	835615	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	47.41
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	150117000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	199998000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12536000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	63393000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	14224000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	77865000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-106284000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	153215000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-28984000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27524000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	62243000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148203000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120679000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58436000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119219000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148203000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120679000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3296000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6534000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	9029000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	375000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	180000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	188000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	72000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	117000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	61000	USD
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2019	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	68000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	318000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1746000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	897000	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	7865000	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	248887000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34776000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14224000	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2019	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	199998000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	65599000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	517000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-72240000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-72240000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	91765000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17204000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	63393000	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	150117000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	-65000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-218000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	129085000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	151047000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20820000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13104000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12536000	USD
CY2021	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	350058000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-642000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	402710000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	196953000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology with the collaborators’ proprietary compounds. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex® recombinant (“Hylenex”), and it works by breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (members of the Takeda group of companies) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma Holding (AstraZeneca PLC announced the completion of its acquisition of Alexion Pharmaceuticals, Inc. in July 2021) (“Alexion”), argenx BVBA (“argenx”), Horizon Therapeutics plc. (Horizon) and ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (“ViiV”). We receive royalties from three of these collaborations, including royalties from sales of one product from the Baxalta collaboration and three products from the Roche collaboration and one product from Janssen collaboration. Future potential revenues from royalties and fees from ENHANZE collaborations and the sales and/or royalties of our approved products will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div>Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div>
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1179032	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.09
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	324831	shares
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk, Sources of Supply and Significant Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectability of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at December 31, 2021 and 2020. Approximately 90% of the accounts receivable balance at December 31, 2021 represents amounts due from Janssen, Roche and Baxalta. Approximately 74% of the accounts receivable balance at December 31, 2020 represents amounts due from Janssen, Roche and Baxalta. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</span></div><div style="margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:56.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped. Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):</span></div><div style="margin-top:11pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:56.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,<br/></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,089 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,644 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,905 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,310 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,594 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,992 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on two third-party manufacturers for the supply of bulk rHuPH20 for use in the manufacture of Hylenex recombinant and our other collaboration products and product candidates. Payments due to these suppliers represented 36% and 75% of the accounts payable balance at December 31, 2021 and 2020, respectively. We also rely on a third-party manufacturer for the fill and finish of Hylenex recombinant product under a contract. There were no payments due to this supplier at December 31, 2021 and 2020.</span></div>
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	622823000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	620000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	622203000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	220220000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	98000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	220310000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	31	security
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	344500000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	620000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	500965000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	220310000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	121238000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	622203000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	220310000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	740910000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	367881000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	443310000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	267594000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	195992000	USD
CY2021	halo	Proceeds From Partner Of License And Collaborative Agreement ProceedsFromPartnerOfLicenseAndCollaborativeAgreement	290900000	USD
CY2021Q4	halo	Accounts Receivable After Allowance For Credit Loss Current Excluding Other Contract Assets AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets	90975000	USD
CY2020Q4	halo	Accounts Receivable After Allowance For Credit Loss Current Excluding Other Contract Assets AccountsReceivableAfterAllowanceForCreditLossCurrentExcludingOtherContractAssets	90730000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	28.06
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4965374	shares
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7000000	USD
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	4276000	USD
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	5772000	USD
CY2021Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	4300000	USD
CY2021Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	4300000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1700000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2021Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	18504000	USD
CY2020Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	25198000	USD
CY2021Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	5422000	USD
CY2020Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	30404000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	14.98
CY2021Q4	halo	Accountsreceivablefromroyalties Accountsreceivablefromroyalties	63555000	USD
CY2020Q4	halo	Accountsreceivablefromroyalties Accountsreceivablefromroyalties	32098000	USD
CY2021Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	4634000	USD
CY2020Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	4033000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7000000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	92115000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	98733000	USD
CY2021Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	1140000	USD
CY2020Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	1003000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	90975000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	97730000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10672000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5813000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17451000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	33738000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	25785000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	21196000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	53908000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	60747000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	47991000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	35048000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3809000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2510000	USD
CY2021Q4	us-gaap	Other Assets OtherAssets	2096000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	4783000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	53896000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	42341000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	13414000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	14067000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40482000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28274000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19891000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18875000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13100000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11582000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6791000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7293000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2003000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	USD
CY2021Q4	halo	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8794000	USD
CY2020Q4	halo	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10593000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3000000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3000000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3300000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4100000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1600000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1700000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1800000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9858000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8078000	USD
CY2021Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	6514000	USD
CY2020Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	4535000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5793000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6468000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2820000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4868000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	24985000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	23949000	USD
CY2021Q4	halo	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	544000	USD
CY2020Q4	halo	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	3466000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24441000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20483000	USD
CY2021	halo	Operating Lease Accretion Of Liability OperatingLeaseAccretionOfLiability	300000	USD
CY2020	halo	Operating Lease Accretion Of Liability OperatingLeaseAccretionOfLiability	500000	USD
CY2019	halo	Operating Lease Accretion Of Liability OperatingLeaseAccretionOfLiability	800000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1900000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2200000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	80900000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2600000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2700000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	3200000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	3100000	USD
CY2019Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	447300000	USD
CY2021Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	369100000	USD
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	370200000	USD
CY2021Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	9080000.00	shares
CY2021	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	21000000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2900000	USD
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	895936000	USD
CY2021Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	460000000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	19262000	USD
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	10211000	USD
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	876674000	USD
CY2021Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	449789000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y1M13D
CY2021Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	878567000	USD
CY2021Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	861738000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	94085000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2013000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2013000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2013000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2013000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	805334000	USD
CY2021Q4	halo	Long Term Debt Including Interest Gross LongTermDebtIncludingInterestGross	907471000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.76
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M21D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	101800000	USD
CY2021Q4	halo	Long Term Debt Interest Gross LongTermDebtInterestGross	11535000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	895936000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	19262000	USD
CY2021Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	876674000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	89419000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	787255000	USD
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16974468	shares
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20820000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17204000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34776000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	33500000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	49700000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10600000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16600000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66200000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16500000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y8M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0036
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0120
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0022
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0167
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0135
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0256
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	halo	Restrictedstockawardholderexerciseprice Restrictedstockawardholderexerciseprice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y
CY2019Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	550000000	USD
CY2020	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	6500000	shares
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	150000000	USD
CY2020	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	23.05
CY2021	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	4600000	shares
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	200000000	USD
CY2021	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	43.02
CY2019Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	550000000	USD
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	22300000	shares
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	24.72
CY2021Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	750000000	USD
CY2021Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	150000000	USD
CY2021Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	3500000	shares
CY2021Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1775945	shares
CY2021Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	42.89
CY2021Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	76179000	USD
CY2021Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1037547	shares
CY2021Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	47.05
CY2021Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	48842000	USD
CY2021Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1562613	shares
CY2021Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	41.40
CY2021Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	64717000	USD
CY2021Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	273210	shares
CY2021Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	37.75
CY2021Q4	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	10320000	USD
CY2021	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	4649315	shares
CY2021	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	43.02
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	200058000	USD
CY2021	halo	Treasury Stock Acquired Fee Cost Per Share TreasuryStockAcquiredFeeCostPerShare	0.02
CY2021Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	500000	shares
CY2021Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	3500000	shares
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	215000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	402710000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	129085000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-72240000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	140646000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	136206000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144329000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	146796000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141463000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144329000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.86
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.95
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.74
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13800000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18600000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33100000	shares
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	2300000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	2700000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2711000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2944000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	124000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2820000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M17D
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	248071000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	130427000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-70737000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	447000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1125000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1514000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	248518000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	129302000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-72251000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42182000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	84278000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	909000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	253000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	109041000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	114357000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1814000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4637000	USD
CY2021Q4	halo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	600000	USD
CY2020Q4	halo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	1081000	USD
CY2021Q4	halo	Deferred Tax Assets Interest Expense Limitation DeferredTaxAssetsInterestExpenseLimitation	0	USD
CY2020Q4	halo	Deferred Tax Assets Interest Expense Limitation DeferredTaxAssetsInterestExpenseLimitation	5536000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3449000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3478000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	155434000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	157995000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	213620000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	199827000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	157495000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13793000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1185000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1002000	USD
CY2021Q4	halo	Deferred Tax Liabilities Convertible Note DeferredTaxLiabilitiesConvertibleNote	17000	USD
CY2020Q4	halo	Deferred Tax Liabilities Convertible Note DeferredTaxLiabilitiesConvertibleNote	11776000	USD
CY2021Q4	halo	Deferred Tax Liabilities Rightof Use Asset DeferredTaxLiabilitiesRightofUseAsset	426000	USD
CY2020Q4	halo	Deferred Tax Liabilities Rightof Use Asset DeferredTaxLiabilitiesRightofUseAsset	733000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	433000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	282000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2061000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13793000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	199800000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	154200000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-9000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-11000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	114000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1251000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	228000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-40000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-117925000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-85000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-37509000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-154192000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	217000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	52188000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	27153000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15173000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	6690000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1942000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1509000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-211039000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-211039000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	44727000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8147000	USD
CY2021	halo	Income Tax Reconciliationworthlessstockinsubsidiary IncomeTaxReconciliationworthlessstockinsubsidiary	0	USD
CY2020	halo	Income Tax Reconciliationworthlessstockinsubsidiary IncomeTaxReconciliationworthlessstockinsubsidiary	-67322000	USD
CY2019	halo	Income Tax Reconciliationworthlessstockinsubsidiary IncomeTaxReconciliationworthlessstockinsubsidiary	0	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-94000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	237000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	318000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2690000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-4117000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	315000	USD
CY2021	halo	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationAmount	3051000	USD
CY2020	halo	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationAmount	1434000	USD
CY2019	halo	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Limitation Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationLimitationAmount	858000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	634000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	47000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	66000	USD
CY2021	halo	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFDIIAmount	-2932000	USD
CY2020	halo	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFDIIAmount	0	USD
CY2019	halo	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFDIIAmount	0	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1091000	USD
CY2021	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	0	USD
CY2020	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	0	USD
CY2019	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	5718000	USD
CY2021	halo	Effective Income Tax Rate Reconciliation Convertible Note Discountin Apic EffectiveIncomeTaxRateReconciliationConvertibleNoteDiscountinAPIC	0	USD
CY2020	halo	Effective Income Tax Rate Reconciliation Convertible Note Discountin Apic EffectiveIncomeTaxRateReconciliationConvertibleNoteDiscountinAPIC	0	USD
CY2019	halo	Effective Income Tax Rate Reconciliation Convertible Note Discountin Apic EffectiveIncomeTaxRateReconciliationConvertibleNoteDiscountinAPIC	13776000	USD
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-154192000	USD
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	217000	USD
CY2019	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-11000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17700000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	19167000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21483000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	20028000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	21000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	41000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	69000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1496000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2357000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	23000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1409000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17692000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	19167000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21483000	USD
CY2021Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0	USD
CY2020Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2200000	USD
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1003000	USD
CY2021	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	8131000	USD
CY2021	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	7994000	USD
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1140000	USD
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	797000	USD
CY2020	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	13276000	USD
CY2020	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	13070000	USD
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1003000	USD
CY2018Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	592000	USD
CY2019	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	7327000	USD
CY2019	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	7122000	USD
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	797000	USD

Files In Submission

Name	View Source	Status
0001159036-22-000014-index-headers.html	Edgar Link	pending
0001159036-22-000014-index.html	Edgar Link	pending
0001159036-22-000014.txt	Edgar Link	pending
0001159036-22-000014-xbrl.zip	Edgar Link	pending
ex1038-nonqualifieddeferre.htm	Edgar Link	pending
ex1039directorsdeferredequ.htm	Edgar Link	pending
ex211subsidiaries2021.htm	Edgar Link	pending
ex231auditorconsent2021.htm	Edgar Link	pending
ex31110k2021.htm	Edgar Link	pending
ex31210k2021.htm	Edgar Link	pending
ex3210k2021.htm	Edgar Link	pending
ex45descriptionofsecurities.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
halo-20211231.htm	Edgar Link	pending
halo-20211231.xsd	Edgar Link	pending
halo-20211231_cal.xml	Edgar Link	unprocessable
halo-20211231_def.xml	Edgar Link	unprocessable
halo-20211231_g1.jpg	Edgar Link	pending
halo-20211231_g2.jpg	Edgar Link	pending
halo-20211231_htm.xml	Edgar Link	completed
halo-20211231_lab.xml	Edgar Link	unprocessable
halo-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2021 Q4 Form 10-K Financial Statement

#000115903622000014 Filed on February 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2021 Q4 Form 10-K Financial Statement

#000115903622000014 Filed on February 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo